Conference News

  • MV disease in children requires modified strategies

    on June 26th, 2017
    AT THE 2017 MITRAL VALVE CONCLAVE NEW YORK (FRONTLINE MEDICAL NEWS) – Repairing mitral valves in pediatric patients must overcome two issues: the wide variability in their anatomy and their growth. Using strategies and techniques common in adult mitral surgery can accomplish good mitral valve func[...]
  • T receptor diversity may predict BCP-ALL response to blinatumomab

    on June 26th, 2017
    AT EHA 2017 MADRID (FRONTLINE MEDICAL NEWS) – For patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), an extensive and diverse T-cell receptor repertoire may be predictive of response to blinatumomab (Blincyto), investigators suggest. Patients with respons[...]
  • Pembrolizumab + rituximab boost response rates in relapsed follicular lymphoma

    on June 26th, 2017
    AT 14-ICML LUGANO, SWITZERLAND (FRONTLINE MEDICAL NEWS) – A novel combination of the anti-programmed death 1 (PD-1) checkpoint inhibitor pembrolizumab (Keytruda) and the anti-CD20 monoclonal antibody rituximab was associated with a high overall response rate (ORR) in patients with relapsed follicu[...]
  • IL-6 nanobody vobarilizumab advances despite equivocal phase II data

    on June 25th, 2017
    AT EULAR 2017 MADRID (FRONTLINE MEDICAL NEWS) – Despite failing its phase II primary endpoint, the single-domain antibody vobarilizumab, being developed for rheumatoid arthritis, will advance to phase III studies. A robust placebo response obscured the strength of clinical response to vobarilizuma[...]
  • CARs race for supremacy against aggressive non-Hodgkin lymphoma

    on June 25th, 2017
    AT EHA 2017 MADRID – Two chimeric antigen receptor T cell (CAR-T) constructs are showing promising activity against treatment-refractory, aggressive forms of non-Hodgkin lymphoma in multicenter clinical trials. In the ZUMA-1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 CAR-T p[...]
  • Biosimilar immunogenicity studies produce no surprises

    on June 25th, 2017
    MADRID (FRONTLINE MEDICAL NEWS) – Two biosimilar tumor necrosis factor inhibitor (TNFi) products are no more immunogenic than their reference biologic counterparts in patients with rheumatoid arthritis (RA), according to the results of two studies presented at the European Congress of Rheumatology[...]
  • Biologics, TNF-inhibitors confer no excess cancer risks upon RA patients

    on June 25th, 2017
    AT EULAR 2017 MADRID (FRONTLINE MEDICAL NEWS) – Biologics and tumor necrosis factor–inhibitors confer very little – if any – risk of malignancy upon those who take them for rheumatoid arthritis, according to a large Swedish registry study. A doubling in the risk of squamous cell carcinoma am[...]
  • Gene editing aims to recreate beneficial mutation in SCD, beta-thalassemia

    on June 25th, 2017
    AT EHA 2017 MADRID – With some genetic sleight-of-hand, investigators hope to mimic a rare, naturally occurring mutation that protects some patients with beta-thalassemia or sickle-cell disease (SCD) from becoming symptomatic. Although human studies have yet to begin, investigators in a biotech co[...]
  • Oral insulin matches glargine in phase II trial

    on June 25th, 2017
    AT THE ADA ANNUAL SCIENTIFIC SESSIONS SAN DIEGO – In an industry-funded phase II trial, researchers say they’ve shown for the first time that oral basal insulin tablets can safely decrease plasma glucose in patients with type 2 diabetes (T2DM). “Oral basal insulin appears safe and efficacious [...]
  • Safety data review finds no increased risk of infection from abatacept

    on June 24th, 2017
    AT EULAR 2017 MADRID (FRONTLINE MEDICAL NEWS) – Abatacept doesn’t appear to increase the risk of opportunistic infections among patients with rheumatoid arthritis, Kevin Winthrop, MD, reported at the European Congress of Rheumatology. After reviewing all of the extant safety data on the drug –[...]
  • Midostaurin improves survival in new AML

    on June 24th, 2017
    FROM THE EHA CONGRESS Adding the multitargeted kinase inhibitor midostaurin to standard chemotherapy led to significantly longer overall and event-free survival compared to placebo and standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients with FLT3 gene mutations, according [...]
  • Ibrutinib dons new anti-GVHD hat

    on June 24th, 2017
    AT EHA 2017 MADRID – Talk about versatility: Ibrutinib (Imbruvica), a drug with marked activity against B-cell malignancies, also appears to be a safe and acceptable option for the treatment of patients with chronic graft vs. host disease (cGVHD) for whom frontline therapies have failed. Among 42 [...]
  • Apremilast eases PsA symptoms in patients who are naive to biologics

    on June 24th, 2017
    AT EULAR 2017 MADRID (FRONTLINE MEDICAL NEWS) – Aprelimast rapidly improved symptoms for patients with active psoriatic arthritis who were naive to biologics, whether or not they were on background methotrexate. Response to the phosphodiesterase 4-inhibitor also increased with time, Peter Nash, MD[...]
Back to top